Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

A Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of PerioSept® (3%) as Adjunct to Scaling and Root Planing in Subjects With Periodontitis

A Phase 2, uncontrolled, open-label, single arm study to evaluate the safety, tolerability and efficacy of PerioSept® (3%) as adjunct to Scaling and Root Planing in subjects with periodontitis.

Study Overview

• Status: Completed
• Conditions: Periodontitis
• Intervention / Treatment: Drug: PerioSept(r)

Detailed Description

Open-label, uncontrolled, single arm study to evaluate PerioSept® as adjunct to Scaling and Root Planing in Subjects with moderate to severe Periodontitis.

Up to 12 adult subjects will be enrolled to obtain at least 10 evaluable subjects.

4 study visits will take place for each enrolled subject (V1-V4 within 120 days). An additional optional follow-up visit (V5) at 6 Months might be added later on. On the baseline visit at Day 1 (V2) and if needed Day 2 (V2a) patients will undergo full mouth SRP followed by administration of PerioSept® 3% gel into gingival dental pockets. Treatment of PerioSept® 3% (without SRP) will be repeated at V3.

Eligible subjects must have a minimum of 4 qualifying target teeth defined as a tooth with at least one periodontal pocket with a probing pocket depth (PPD) >= 6mm and bleeding on probing (BOP) at baseline defined as study pockets. All study pockets will be treated with SRP and PerioSept®. Additional teeth identified by investigator as needing SRP per standard of care but not meeting target teeth criteria will be defined as non-target teeth/treatment sites and may also be treated with SRP and PerioSept®.

Dental parameters will only be assessed on the target teeth and each of the 6 sites associated with these teeth (assessment sites). Thus, each eligible patient will have at least 4 Target teeth, a minimum of 4 study pockets and a minimum of 24 assessment sites (6 sites per tooth x 4 target teeth, inclusive of the 4 study pockets) that will be assessed for all study outcome measures.

Overall for all 10 evaluable patients there will be at least 40 target teeth, 40 study pockets and 240 sites for which the study outcome measures will be assessed as specified further below.

Assessments will be conducted over a 12 weeks' and optional 24 weeks' (3 and 6 months respectively) period including safety assessments, assessments of dental parameters (PPD, Clinical attachment level, BOP, recession, Plaque index, Gingival Index) and tolerability assessment.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77063
      • Perio Health Professionals

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects male or female 18 to 80 years of age, inclusive.
• Subjects must be diagnosed with moderate to severe generalized periodontitis (ADA Classification Case Type III or IV) as determined by the investigator.
• Subjects must have at least 4 qualifying target teeth (having a dental pocket with PPD ≥ 6mm and BOP) (teeth having no endodontic disease - treated or untreated).
• Subjects must have at least 12 teeth in the functional dentition, excluding second and third molars In subjects with limited dentition, tooth loss should not be due to traumatic occlusion
• Females of childbearing potential must agree to use of birth control (hormonal, barrier method or abstinence). Hormonal contraceptives must have started not fewer than 30-days before baseline visit/Day 1.
• Subjects must sign informed consent document(s) prior to initiation of any study-specific procedures and treatments.
• Subjects who are able and willing to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

• History of and/or known risk of life-threatening anaphylactic reactions to taurolidine, any of the components in the investigational drug product.
• Presence of an acute periodontal abscess.
• Subjects with healing disorders (e.g. uncontrolled diabetes mellitus, oral cancer) that could compromise wound healing and/or preclude periodontal surgery.
• Subjects who are taking medications that compromise wound healing presenting with clinical evidence of secondary hyperplastic gingival tissue reactions (e.g. calcium channel blockers or anti-seizure medications)
• Pregnant or nursing female subjects; women of child-bearing potential must have a negative urine pregnancy test.
• Use of systemic antibiotics and, topically applied oral antibiotics and other antimicrobial agents (e.g., chlorhexidine) within 45 days prior to Day 1 or expected use during the study trial period.
• An existing condition that may warrant use of antibiotics during the study trial period.
• Known Human Immunodeficiency Virus infection or other immunodeficiency syndrome.
• Subjects with active infectious diseases (e.g. hepatitis, HIV or tuberculosis)
• Use of agents known to affect periodontal status during the trial and/or use within 45 days prior to Day 1 e.g. immunosuppressants, nasal or oral corticosteroids, calcium channel blockers, phenytoin or anticoagulants.
• Heavy smokers/tobacco users are excluded: defined as those smoking ≥ 10 cigarettes or ≥ 4 cigars or ≥ 4 pipes per day (smokeless nicotine products are NOT excluded)
• Participation in another clinical study with an investigational agent within 90 days prior to Day 1.
• Subjects who received oral health treatments/interventions within 90 days of Day 1, which the investigator believes may interfere with the periodontal parameters to be assessed in this study (e.g., significant dental and/or gum/oral tissue work).
• SRP or periodontal surgery within 12 months prior to Day 1.
• Subject who have a medical and/or dental condition (e.g. a current clinically unstable occlusal situation) and/or use medications/supplements which the investigator believes makes him/her unsuitable for participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SRP and 3% PerioSept(r); Scaling and root planing followed by 3% PerioSept® drug administration	Drug: PerioSept(r); Scaling and root planing followed by 3% PerioSept(r) administration; Other Names: Taurolidine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy: Mean probing pocket depth (PPD) reduction (mm) of all study pockets (pockets with PPD > 6 mm and bleeding on probing (BOP) at baseline on target teeth) at subject level and across all subjects	Mean probing pocket depth (PPD) reduction (mm) of all study pockets (pockets with PPD > 6 mm and bleeding on probing (BOP) at baseline on target teeth) at subject level and across all subjects	Baseline, Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy: Mean PPD reduction (mm) of all study pockets per patient	Mean PPD reduction (mm) of all study pockets per patient	Baseline, Week 4
Efficacy: Number of study pockets changing from ≥ 6 mm PPD to ≤5 mm PPD	Number of study pockets changing from ≥ 6 mm PPD to ≤5 mm PPD	Baseline; Week 4, 12
Efficacy: Change in Clinical attachment level (CAL) of all study pockets	Change in CAL of all study pockets	Baseline; Week 4, 12
Efficacy: Change in plaque index (PI) of all study pockets	Change in PI of all study pockets	Baseline; Week 4, 12
Efficacy: Change in gingival index (GI) of all study pockets	Change in GI of all study pockets	Baseline; Week 4, 12
Efficacy: Change in BOP of all study pockets	Change in BOP of all study pockets	Baseline; Week 4, 12
Efficacy: Change in recession (REC) of all study pockets	Change in REC of all study pockets	Baseline; Week 4, 12
Efficacy: Change in PPD of all 6 assessment sites on target teeth	Change in PPD of all 6 assessment sites on target teeth	Baseline; Week 4, 12
Efficacy: Change in CAL of all 6 assessment sites on target teeth	Change in CAL of all 6 assessment sites on target teeth	Baseline; Week 4, 12
Efficacy: Change in PI of all 6 assessment sites on target teeth	Change in PI of all 6 assessment sites on target teeth	Baseline; Week 4, 12
Efficacy: Change in GI of all 6 assessment sites on target teeth	Change in GI of all 6 assessment sites on target teeth	Baseline; Week 4, 12
Efficacy: Change in BOP of all 6 assessment sites on target teeth	Change in BOP of all 6 assessment sites on target teeth	Baseline; Week 4, 12
Efficacy: Change in REC of all 6 assessment sites on target teeth	Change in REC of all 6 assessment sites on target teeth	Baseline; Week 4, 12
Safety/tolerability: Assessment of treatment-emergent adverse events based on dental examination	Assessment of treatment-emergent adverse events based on dental examination	Day -45 till Month 6
Tolerability: Clinician assessment of local irritation to include assessments of redness/erythema, inflammation/swelling, blisters or erosions, suppuration and other findings at the study treatment pockets or surrounding tissue.	Clinician assessment of local irritation to include assessments of redness/erythema, inflammation/swelling, blisters or erosions, suppuration and other findings at the study treatment pockets or surrounding tissue.	Day 1, 2, 28
Tolerability: Subject reported tolerability for pain, burning/stinging, sensitivity and taste based on a numeric rating scale	Subject reported tolerability for pain, burning/stinging, sensitivity and taste based on a numeric rating scale	Day 1, 2, 28

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory: Clinician reported outcome for delivery device handling and ease of use	Clinician reported outcome for delivery device handling and ease of use	Day 1, 2
Exploratory: Microbiological counts of periodontal pathogens in biofilm samples of 4 study pockets	Microbiological counts of periodontal pathogens in biofilm samples of 4 study pockets	Baseline (before treatment); Week 4, 12

Collaborators and Investigators

• Sponsor: Geistlich Pharma AG
• Investigators: Principal Investigator: Michael McGuire, DDS, PerioHealth Clinic Houston

Study record dates

Study Major Dates

• Study Start (Actual): August 26, 2019
• Primary Completion (Actual): June 10, 2020
• Study Completion (Actual): September 25, 2020

Study Registration Dates

• First Submitted: September 13, 2019
• First Submitted That Met QC Criteria: September 17, 2019
• First Posted (Actual): September 18, 2019

Study Record Updates

• Last Update Posted (Actual): October 19, 2020
• Last Update Submitted That Met QC Criteria: October 16, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: Periodontitis; taurolidine; PerioSept
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Periodontal Diseases; Mouth Diseases; Periodontitis; Anti-Infective Agents, Local; Anti-Infective Agents; Antineoplastic Agents; Taurolidine
• Other Study ID Numbers: PSPD 2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No